Becaplermin

贝卡普勒明

Report date: 2025/05/06 15:48:31

Base Information

Drug NameBecaplermin
Drug Alias NameBecaplerminaBecaplerminumGemesisRegranexRWJ-60235 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionPlatelet-derived growth factor receptor beta agonists
TargetsPlatelet-derived growth factor receptor beta
Therapy Area/IndicationsLower extremity diabetic neuropathic ulcersUlcerSkin Ulcer +[8] 
Global Approved IndicationsLower extremity diabetic neuropathic ulcersUlcerSkin Ulcer
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1997/12/16
Country/TerritoryCanadaUnited StatesSweden +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesLynch Regenerative Medicine LLCSmith & Nephew Healthcare Ltd
Inactive CompaniesJanssen-Cilag International NvNewron Sweden AbMcmaster University +[4] 
Active IndicationsLower extremity diabetic neuropathic ulcersUlcer
Inactive IndicationsSkin UlcerFoot UlcerVaricose Ulcer +[6] 

Other Information

ATC CodeA01AD08D03AX06
Related LinksWikipediaDrugBankKEGG